Delving into the Latest Updates on Dostarlimab-gxly with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Dostarlimab, Dostarlimab subcutaneous injection(Tesaro), Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer

+ [12]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsUrogenital DiseasesNervous System Diseases+ [10]

Active Indication

Advanced Endometrial CarcinomaRecurrent Endometrial CancerMismatch repair-deficient Solid Tumors+ [81]

Inactive Indication

Advanced Bile Duct CarcinomaClear Cell SarcomaGestational Trophoblastic Disease+ [6]

Originator Organization

AnaptysBio, Inc.

Active Organization

Tesaro, Inc.

GSK PlcGlaxoSmithKline Trading Services Ltd.

+ [7]

Inactive Organization-

License Organization

AnaptysBio, Inc.Sagard Healthcare Royalty Partners LP

GSK Plc

+ [1]

Drug Highest PhaseApproved

First Approval Date

European Union (21 Apr 2021),

Microsatellite instability-high Endometrial CarcinomaMismatch repair-deficient Endometrial Carcinoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Priority Review (Australia), Commissioner's National Priority Voucher (United States), Fast Track (United States)

Login to view timeline

Structure/Sequence

Sequence Code 315609369H

Source: *****

Sequence Code 315609370L

Source: *****

The BeeHive study is an investigator-initiated, single center, open-label phase II clinical trial that is designed to conduct a comprehensive multiomic biomarker evaluation across two single-arm cohorts to elucidate mechanisms of response and resistance in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). It is anticipated that about 20 patients will be enrolled in Cohort A and an additional of 10 patients will be enrolled in Cohort B.

Start Date02 Feb 2026

Sponsor / Collaborator

University Health Network

[+1]

NCT07381777

/ Not yet recruitingPhase 2IIT

Phase II Randomized Trial of XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients - IMMUNOSTAR Trial GOIRC-02-2024

This is a phase II, multicenter, randomized (2:1) controlled, clinical trial to evaluate the preliminary efficacy and safety of consolidation chemotherapy (XELOX) plus dostarlimab after standard long-course CRT (ARM A) compared to XELOX alone (ARM B) in patients with pMMR/MSS or MSI-Low LARC (cT3-4 cN0, any cT cN+) candidate to receive standard long course CRT followed by TME. After the surgery, the patients in ARM A will be randomized (1:1) to receive adjuvant dostarlimab (ARM A1) versus follow-up (ARM A2), and in ARM B only follow-up.
If clinical complete responses (cCR) are documented after consolidation treatment, the patient may choose not to proceed with surgery and pursue nonoperative management (NOM).

Start Date31 Jan 2026

Sponsor / Collaborator

GSK Plc

CTIS2024-519798-20-00

/ RecruitingPhase 2IIT

Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial - GOIRC-02-2024

Start Date15 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Dostarlimab-gxly

Login to view more data

100 Translational Medicine associated with Dostarlimab-gxly

Login to view more data

100 Patents (Medical) associated with Dostarlimab-gxly

Login to view more data

203

Literatures (Medical) associated with Dostarlimab-gxly

31 Dec 2026·PLATELETS

Immune thrombocytopenia triggered by dostarlimab in a patient with endometrial carcinoma: first reported case

Article

Author: Pazmiño-Zambrano, M. Belén ; García-Jaén, Pablo ; González-Porras, José Ramón ; Bastida, José María ; Reguera-Puertas, Pablo ; Fernández-Sánchez, Adolfo ; Puerta-Vázquez, Carlos

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for various malignancies, but they are associated with a range of immunerelated adverse events, including rare hematological complications. Immune thrombocytopenia (ITP) has been reported with other antiPD1 agents such as nivolumab and pembrolizumab, but to date, no cases have been described with dostarlimab. We report the first case of ITP in a patient receiving dostarlimab for relapsed endometrial carcinoma. A 55yearold woman developed severe thrombocytopenia (3 × 10⁹/L) accompanied by rectal bleeding, resulting in a lifethreatening condition. Secondary causes were excluded, and bone marrow findings supported a diagnosis of ITP. Initial treatment with highdose corticosteroids and intravenous immunoglobulin achieved only a partial response, while sustained platelet recovery was obtained with the addition of romiplostim. The patient remained on dostarlimab following hematological recovery without further episodes of ITP. This case highlights a potentially lifethreatening adverse effect of a widely used immunotherapy and underscores the importance of early recognition and timely escalation of treatment in ICIinduced ITP.

01 Apr 2026·Gynecologic Oncology Reports

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials

Article

Author: Richardson, Michael T ; Chan, John K ; Choi, Eunji ; Francoeur, Alex A ; Kapp, Daniel S ; Johnson, Caitlin R ; Tewari, Krishnansu S ; Liang, Su-Ying ; Brameld, Max ; File, Brittany

Background:

The purpose of this project was to evaluate the cost-effectiveness of novel FDA approved regimens incorporating immunotherapy into upfront treatment with chemotherapy in advanced or recurrent endometrial cancer in the mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) cohorts.

Methods:

Partitioned survival models were established based on the RUBY, NRG-GY 018, and DUO-E trials, as well as available FDA data. Incremental cost-effectiveness ratios (ICERs) were estimated based on quality adjusted progression free life years saved (QA-PFLYS). Tree Age software was used to perform partitioned survival modeling. Outcomes for dMMR and pMMR groups were compared based on the current FDA approvals. Costs were obtained from Redbook Micromedex pricing and adjusted for inflation from study activation to public dissemination of trial results.

Results:

The addition of pembrolizumab, dostarlimab, or durvalumab to chemotherapy in patients with dMMR tumors resulted in improvements in progression free life years saved. Based on QA-PFLYS, the ICER for pembrolizumab was $217,713, followed by $351,280 for durvalumab, and $451,750 for dostarlimab. When continuing durvalumab for 2 years, the ICER was $262,087. When looking at patients with pMMR tumors, the ICER for pembrolizumab was $250,535 while the ICER for dostarlimab was $1,349,776.

Conclusions:

Recognizing existing differences in study design, both pembrolizumab and durvalumab may be more cost effective than dostarlimab in our model. This appears to largely be driven by differences in duration of maintenance therapy rather than differences in effectiveness or individual drug cost. Immunotherapy does not appear to be as cost effective in the pMMR population.

01 Apr 2026·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Real-world evidence for 10 oncology drugs approved in the last 5 years: A comprehensive narrative synthesis

Review

Author: Oggionni, Emanuela ; Balconi, Elena ; Parati, Maria Chiara ; Rossitto, Mauro ; Petrò, Daniela ; Petrelli, Fausto ; Ghilardi, Mara ; Colombo Zefinetti, Lara ; Dottorini, Lorenzo ; Borgonovo, Karen ; Castelli, Emanuela ; Dognini, Giuseppina ; Zambelli, Alberto

IMPORTANCE:

Randomized controlled trials (RCTs) establish the efficacy of new oncology drugs but often exclude older adults, patients with comorbidities, and individuals with poorer performance status. Real-world evidence (RWE) is therefore essential to determine whether trial benefits translate to the broader populations treated in routine practice.

OBJECTIVE:

To synthesize contemporary RWE on the effectiveness and safety of ten oncology drugs approved between 2020 and 2025 for solid tumors, focusing on studies with ≥ 100 patients to maximize robustness and generalizability.

EVIDENCE REVIEW:

A systematic search of PubMed/MEDLINE, Embase, Scopus, Web of Science, and major conference proceedings (ASCO, ESMO, AACR) identified observational cohorts, registries, expanded-access programs, and claims-based studies published from January 2020 to January 2025.

FINDINGS:

Twenty studies (N > 3400) met inclusion criteria: breast cancer (9), lung cancer (7), urothelial carcinoma (3), and endometrial cancer (1). In breast cancer, sacituzumab govitecan reproduced ASCENT outcomes (ORR 27-30 %; PFS 4.8-5.2 months), trastuzumab deruxtecan achieved ORRs near 70 % in HER2-positive disease and median PFS 7.5 months in HER2-low cohorts, and elacestrant showed real-world time-to-next-treatment of 7.9-10.8 months in ESR1-mutant ER+ /HER2 - disease. In NSCLC, sotorasib and adagrasib demonstrated ORRs of ∼28-34 % and PFS 3.5-6 months, selpercatinib provided durable disease control, and MET inhibitors (capmatinib, tepotinib) yielded PFS around 6-7 months. In urothelial carcinoma, enfortumab vedotin produced ORRs of 31-73 % across datasets. In endometrial cancer, dostarlimab generated highly durable responses in dMMR/MSI-H disease.

CONCLUSIONS:

RWE confirms the effectiveness and safety of multiple recently approved oncology drugs reinforcing the external validity of RCTs.

356

News (Medical) associated with Dostarlimab-gxly

01 Apr 2026

·www.biospace.com

LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is available on the Company’s website, , and on the SEC’s website, . “2025 was a transformative and highly productive year for our Company,” said Geordan Pursglove, who was named LIXTE’s Chairman and Chief Executive Officer in June 2025. “We strengthened LIXTE’s foundation by assembling an experienced new management team and enhancing our Board, positioning LIXTE with the leadership needed to execute our strategic priorities. Operationally, we made important progress advancing our lead compound, LB-100, including expanding clinical trial enrollment and adding a prestigious new clinical site. We also completed a strategic acquisition that expanded our platform and will introduce an additional dimension of cancer treatment options to augment our long-term growth opportunities. “Equally important, we successfully raised capital to reinforce our balance sheet and provide the financial flexibility to continue investing in product development. Together, we believe these achievements will position LIXTE to deliver meaningful innovation for patients and enhance long-term shareholder value,” Pursglove added. 2025 Operational Highlights Management and board changes : Geordan Pursglove was appointed Chairman, Chief Executive Officer and President in June 2025; LIXTE’s former CEO, Bas van der Baan, was named Chief Scientific Officer; Jason Sawyer, Michael Holloway, Lourdes Felix and Guy Primus joined the Company’s Board of Directors; and Peter Stazzone was named Chief Financial Officer. The new board members succeeded Mr. van der Baan and René Bernards, PhD, who was named Chairman of LIXTE’s Scientific Advisory Board. More than $11 million was raised in two registered direct offerings and a private placement during the year. Funds are being deployed for general corporate purposes and working capital. The Company relocated its corporate headquarters to Boca Raton. The Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University was added as a second site in a clinical trial combining the LIXTE’s proprietary compound LB-100 with GSK’s Dostarlimab to treat ovarian clear cell cancer. Collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK was further expanded in an ongoing clinical trial with LB-100. The number of enrollments in the trial will double to 42 patients, after successfully attaining the initial target of 21 patients earlier in the year. In November, LIXTE completed the acquisition of Liora Technologies Europe Ltd., a UK-based development-stage company pioneering electronically controlled proton therapy systems for treating tumors in various types of cancers. The acquisition included Liora’s proprietary flagship technology LiGHT System, which is expected to provide significant advantages over currently available technologies for treating tumors with proton therapy. About LIXTE Biotechnology Holdings, Inc. LIXTE Biotechnology Holdings, Inc . is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information can be found at . Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at . Forward-Looking Statement Disclaimer This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors. Readers are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at . The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For more information about LIXTE, contact: info@lixte.com General Phone: (631) 830-7092; Investor Phone: (888) 289-5533 or PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962

Executive ChangeAcquisition

27 Mar 2026

·endpoints.news

AnaptysBio spins out biotech operations; Affibody's data in hidradenitis suppurativa

Plus, news about Zenas and Ysios Capital: 🌀 AnaptysBio’s spinout: The independent public company, called First Tracks Biotherapeutics, is expected to start trading on April 20. It will launch with $180 million in cash and three lead assets in the clinic for autoimmune and inflammatory diseases. Meanwhile, Anaptys will focus on managing its “royalty streams,” including collaborations with GSK for Jemperli and with Vanda for imsidolimab. — Nicole DeFeudis 📊 Affibody touts durability for dermatology candidate: The Swedish biotech said its experimental hidradenitis suppurativa therapy izokibep showed “sustained efficacy” in patients who continued to take the drug for another 16 weeks in a Phase 3 trial. Patients who had started on placebo but crossed over to treatment with izokibep saw “notable rates of response.” CEO David Bejker said in a news release that the results “strengthen our confidence in izokibep.” Acelyrin had licensed the candidate, but handed back the rights last year. — Nicole DeFeudis 💰 Zenas expects $300M from offering: About two-thirds will come from convertible notes with the remainder to be funneled from a common stock sale, the company said . The raise follows a rocky start to the year, after Zenas was punished by investors for Phase 3 data of an autoimmune treatment that disappointed when compared to an already approved competitor from Amgen. The data led Zenas’ stock to fall more than 50% in early January. — Max Bayer 🇪🇸 Ysios Capital unveils new €100M fund: Dubbed InceptionBio, the fund will prioritize company creation and early-stage investments with a heavy emphasis on Spanish biotechs. Ysios said in its announcement that InceptionBio had already closed on its first company, in collaboration with the national Centre for Technological Development and Innovation. The investment firm hopes that InceptionBio would help to launch at least three new companies this year. — Max Bayer

Phase 3Clinical Result

25 Mar 2026

·www.fiercepharma.com

Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech

Biogen will hand Alteogen $20 million upfront for help developing subcutaneous formulations of two unnamed biologics using Alteogen’s Hybrozyme technology and its recombinant human hyaluronidase ALT-B4. After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another Big Pharma partner in Biogen. Biogen will hand Alteogen $20 million upfront for help developing subcutaneous formulations of two unnamed biologics using Alteogen’s Hybrozyme technology and its recombinant human hyaluronidase ALT-B4.As part of the license agreement, Alteogen is in line to receive another $10 million should Biogen kick off development of the second product, and the company is further eligible to receive up to $549 million tied to potential development and regulatory milestones, plus sales targets on the two products combined. Alteogen would also be up for royalties on net sales of the prospective subQ medicines should they make it to market, the company said in a March 25 press release. As part of the arrangement, Biogen also has an option to leverage Alteogen’s technology to develop a third unnamed product. ALT-B4, which also goes by the name berahyaluronidase alfa, is a recombinant human hyaluronidase developed using Alteogen’s Hybrozyme platform. The company’s hyaluronidase enzyme permits the “rapid and efficient dispersion and absorption of co-administered therapeutics” and has been designed to help convert biologics typically administered via intravenous infusion into subcutaneous formulations, Alteogen explained in its release. “We are very pleased to enter into this partnership and look forward to advancing innovative therapies together for patients," Tae-Yon Chun, Alteogen’s CEO, said of the Biogen tie-up in Wednesday’s announcement. The partners did not clarify which Biogen drugs they will attempt to reformulate for subcutaneous delivery. Earlier this year, Alteogen pulled GSK into ALT-B4’s orbit, linking up under another $20 million upfront deal to specifically develop a subcutaneous formulation of the British pharma’s checkpoint inhibitor Jemperli (dostarlimab). Alteogen stands to gain up to $265 million more from the deal tied to development, regulatory and sales milestones and would once again be in line for royalties if the reformulated product goes commercial. Since 2024, Alteogen has also inked similar deals with the likes of Daiichi Sankyo on its AstraZeneca-partnered antibody-drug conjugate Enhertu as well as with AZ around potential subQ oncology products more broadly.

License out/in

100 Deals associated with Dostarlimab-gxly

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Dostarlimab-gxly	L01XC	DB15627

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Advanced Endometrial Carcinoma	European Union	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Advanced Endometrial Carcinoma	Iceland	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Advanced Endometrial Carcinoma	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Advanced Endometrial Carcinoma	Norway	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Recurrent Endometrial Cancer	European Union	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Recurrent Endometrial Cancer	Iceland	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Recurrent Endometrial Cancer	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Recurrent Endometrial Cancer	Norway	GlaxoSmithKline Trading Services Ltd.	12 Jan 2024
Mismatch repair-deficient Solid Tumors	United States	GlaxoSmithKline LLC	17 Aug 2021
Microsatellite instability-high Endometrial Carcinoma	European Union	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021
Microsatellite instability-high Endometrial Carcinoma	Iceland	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021
Microsatellite instability-high Endometrial Carcinoma	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021
Microsatellite instability-high Endometrial Carcinoma	Norway	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021
Mismatch repair-deficient Endometrial Carcinoma	European Union	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021
Mismatch repair-deficient Endometrial Carcinoma	Iceland	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021
Mismatch repair-deficient Endometrial Carcinoma	Liechtenstein	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021
Mismatch repair-deficient Endometrial Carcinoma	Norway	GlaxoSmithKline Trading Services Ltd.	21 Apr 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	United States	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	China	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	Japan	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	Argentina	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	Belgium	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	Brazil	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	Bulgaria	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	Canada	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	Finland	GSK Plc	10 Jun 2024
PD-L1 positive Non-Small Cell Lung Cancer	Phase 3	France	GSK Plc	10 Jun 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESGO2026	Not Applicable	Recurrent Endometrial Cancer dMMR	28	Dostarlimab plus Carboplatin and Paclitaxel (high SII (>800))	cufatoyjbb(avggsrydea) = Arthralgia occurred in 29.5% of patients in the LSG and 54.5% in the HSG egczupxcdi (vpzjntbzvl ) View more	Positive	28 Feb 2026
ESGO2026	Not Applicable	Microsatellite instability-high Endometrial Carcinoma First line dMMR \| MSI-H	37	Dostarlimab plus Carboplatin and Paclitaxel (dMMR/MSI-H + endometrial cancer)	gfqiiihidl(wfhtizmzrl) = The most common adverse events were diarrhea and arthralgia. Diarrhea occurred in 40% of patients, including 6 patients with grade 3-4 events. Arthralgia occurred in 35% with only 1 case of grade 3. Other immune-related toxicities were observed in 59.5% of patients. frmectrtsk (lrionpzgbk )	Positive	28 Feb 2026
DUO-E (ESGO2026)	Phase 3	Mismatch repair-deficient Endometrial Carcinoma First line pMMR	759	Durvalumab plus carboplatin/paclitaxel followed by durvalumab plus olaparib	dfdbxtzcrl(fllztmtchn): OR = 0.99 (95.0% CI, 0.58 - 1.67) View more	Positive	28 Feb 2026
				Dostarlimab plus carboplatin/paclitaxel followed by dostarlimab
NCT06256588 (JADE, Pubmed \| Future Oncol)	Phase 3	Squamous Cell Carcinoma of Head and Neck PD-L1-expressing	360	Dostarlimab	orqzkvqacv(dnwddmqqco) = shoexjegqw egswnupvta (qvsozjejav )	Positive	26 Jan 2026
				Placebo	orqzkvqacv(dnwddmqqco) = vzgdwbxaei egswnupvta (qvsozjejav )
NCT04544995 (SCOOP, CTgov)	Phase 1	Adrenocortical Carcinoma \| Relapsed Solid Neoplasm \| Solid tumor ... View more	47	Niraparib+Dostarlimab (Part 1A Cohort 0: Niraparib 100 Milligram (mg) + Dostarlimab 3 mg/Kilogram (kg))	brrtougucm = qqmxctnlrl oszmlbzpnc (wcchtvthwy, amlznhaczh - wsbxtleizn) View more	-	21 Jan 2026
				Niraparib+Dostarlimab (Part 1A Cohort 1A: Niraparib 100 mg + Dostarlimab 7.5 mg/kg)	brrtougucm = ayexczzdwp oszmlbzpnc (wcchtvthwy, mxqqmqhnyt - vawpcmbesx) View more
NCT05855200 (AZUR-2, Pubmed \| Future Oncol)	Phase 3	Mismatch repair-deficient Colonic Cancer Neoadjuvant dMMR \| MSI-H	948	Neoadjuvant dostarlimab 500 mg + surgery + adjuvant dostarlimab 1000 mg	yokxzvkjto(uzvlduiclj) = koffrvwfvb lpbjqqjzxr (gdowjajjcv )	Positive	14 Jan 2026
NCT03602859 (FIRST/ENGOT-OV44 \| FIRST-ENGOT-OV44 \| FIRST, CTgov)	Phase 3	Primary peritoneal carcinoma \| Ovarian Epithelial Carcinoma \| Fallopian Tube Carcinoma	1,400	Carboplatin+Paclitaxel+Niraparib+Dostarlimab (Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2))	qoxuvvgmia(zrhnotvety) = kbepgaueid ndalxonmxb (aeaiunuvhi, swwjpoyqbo - vutnuushjl) View more	-	31 Dec 2025
				Carboplatin+Paclitaxel+Niraparib+Dostarlimab (Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3))	qoxuvvgmia(zrhnotvety) = hkxtwlhajp ndalxonmxb (aeaiunuvhi, avljnzzslg - myzyrmjjli) View more
SABCS2025	Phase 2	BRCA mutation positive Breast Cancer Neoadjuvant BRCA-Mutation Positive \| Hormone-Receptor Positive	34	Niraparib + Dostarlimab (HR+ BRCA-mutated breast cancer)	viyyylhcyd(jxdgdoxrko) = Commonly reported adverse events included rash (25.0%), elevated liver function tests (18.8%), diarrhea (12.5%), and hypertension (12.5%). tyqlpdctwn (anhlaaummt ) View more	Positive	10 Dec 2025
				Pembrolizumab + Carboplatin (HR+ BRCA-mutated breast cancer)
ESMO_ASIA2025	Not Applicable	Microsatellite instability-high cancer microsatellite instability-high (MSI-H)	83	Immune Checkpoint Inhibitor	bilikzhhzp(wtjzvbjmfv) = wxvahrkdog yxueevezwl (cqkqroddme ) View more	Positive	05 Dec 2025
NCT04581824 (PERLA, ESMO2025)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma First line ctDNA \| bTMB	189	Dostarlimab + chemotherapy	yoxjcgsneb(ibbnuaivie) = nfjjfpwufu qlzhxxbxaz (shgohebvcs ) View more	Positive	17 Oct 2025
				Pembrolizumab + chemotherapy	yoxjcgsneb(ibbnuaivie) = mhoorlwqga qlzhxxbxaz (shgohebvcs ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data